When Alnylam Pharmaceuticals announced it would join the Alliance for Genomic Discovery (AGD), formed by Illumina and Nashville Biosciences, as the ninth biopharma member, the move signaled more than a new partnership. It marked another step toward reshaping precision medicine with large-scale, ancestrally diverse genomic data and detailed clinical records—resources long dominated by European cohorts.

“Genetic evidence is one of the most powerful tools we have to improve drug discovery,” Will J. Ferguson, vice president of pharmaceutical and biotech collaborations at Illumina, told Inside Precision Medicine . “AGD was designed to bring together all the pieces—sequencing infrastructure, informatics, and deep clinical data—to drive discoveries that can lead to better, faster treatment

See Full Page